Sen. Grassley's Proposed Drug Safety Office Would Have Labeling Authority
This article was originally published in The Pink Sheet Daily
Executive Summary
Finance Committee chairman is considering the feasibility of giving an independent drug safety office authority to suspend direct-to-consumer ads and marketing. The senator expects to offer legislation that would create the drug safety office soon, although the timeline may change based upon other legislators' actions.
You may also be interested in...
FDA Safety Act Proposes Fines For Failure To Comply With Drug Safety Office
Center for Postmarket Drug Evaluation & Research would be able to levy fines starting at $250,000 for failure to complete postmarketing studies on time and for failure to comply with "corrective actions" under the legislation. FDASA would give the independent drug safety office authority over labeling changes and promotional materials.
FDA Safety Act Proposes Fines For Failure To Comply With Drug Safety Office
Center for Postmarket Drug Evaluation & Research would be able to levy fines starting at $250,000 for failure to complete postmarketing studies on time and for failure to comply with "corrective actions" under the legislation. FDASA would give the independent drug safety office authority over labeling changes and promotional materials.
Drug Safety Legislation To Be Introduced April 27
Sens. Grassley and Dodd are proposing the creation of a “Center for Post-market Drug Evaluation & Research” that would be independent from FDA’s existing drug safety infrastructure. Proposals for an independent drug safety office have elicited mixed reactions from the agency.